Table 1.
Study patient demographics: all patients vs LN-positive patients.
| All | LN-positive patients |
|
|---|---|---|
| Number of Patients | 1489 | 231 |
| Median Age Years (IQR) Gender | 3.0 (1.0–5.0) | 4.0 (2.0–5.0) |
| Female (%) | 800 (53.7) | 122 (52.8) |
| Male (%) | 689 (46.3) | 109 (47.2) |
| Race/Ethnicity | ||
| White (%) | 738 (49.6) | 111 (48.1) |
| Black (%) | 256 (17.2) | 36 (15.6) |
| Hispanic (%) | 400 (26.9) | 68 (29.4) |
| Other (%) | 84 (5.6) | 14 (6.1) |
| Unknown (%) | 11 (0.7) | 2 (0.9) |
| Laterality | ||
| Right (%) | 739 (49.6) | 88 (38.1) |
| Left (%) | 750 (50.4) | 143 (61.9) |
| Median Tumor Size Centimeters (IQR) | 11 (8.0–13.5) | 12.0 (0.5–13.85) |
| SEER Summary Stage | ||
| Unknown (%) | 18 (1.2) | |
| Localized (%) | 643 (43.2) | |
| Regional (%) | 489 (32.8) | 132 (57.1) |
| Distant | 339 (22.8) | 99 (42.9) |
| Median LNY (IQR) | 3 (1–7) | 6 (3–11) |
| 0 (%) | 246 (16.5) | |
| 1–3 (%) | 483 (32.4) | 76 (32.9) |
| 4–6 (%) | 307 (20.6) | 59 (25.5) |
| 7–9 (%) | 145 (9.7) | 27 (11.7) |
| 10–12 (%) | 85 (5.7) | 23 (10.0) |
| >12 (%) | 155 (10.4) | 46 (19.9) |
| Unknown (%) | 68 (4.6) | |
| Median LNs Positive (IQR) | 0 (0–0) | 2 (1–14) |
| Unknown (%) | 16 (1.1) | |
| 0 (%) | 984 (66.1) | |
| 1 (%) | 114 (7.7) | 113 (48.9) |
| ≥2 (%) | 119 (8.0) | 118 (51.1) |
| LND (IQR) | 0.38 (0.18–0.70) | |
| Radiation (%) | 721 (48.4) | 216 (93.5) |
| Chemotherapy (%) | 1345 (90.3) | 225 (97.4) |
| Estimated five-year OS (95% CI) | 92.2% (90.5–93.7) | 83.5% (77.2–88.2) |